AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows - AstraZeneca ( NASDAQ:AZN )
AstraZeneca Plc AZN released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi ( durvalumab ) in combination with standard-of-care chemotherapy for advanced biliary tract cancer ( BTC ) .
https://www.benzinga.com/general/biotech/24/04/38269196/astrazenecas-imfinzichemo-combo-doubles-overall-survival-in-biliary-tract-cancer-patients-at-3-ye